Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

PURPOSE: The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as first-line therapy for B-cell non-Hodgkin lymphoma (B-NHL). We report the pharmacokinetics...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Shemesh, Colby S., Agarwal, Priya, Lu, Tong, Lee, Calvin, Dere, Randall C., Li, Xiaobin, Li, Chunze, Jin, Jin Y., Girish, Sandhya, Miles, Dale, Lu, Dan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188703/
https://ncbi.nlm.nih.gov/pubmed/32222808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04054-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados